PharmaResearch Co., Ltd. (214450.KQ) Stock

214450.KQ logo

PharmaResearch Co., Ltd.

214450.KQSouth Korea
Healthcare

Company profile

PharmaResearch reported revenue of 350.12 billion KRW for fiscal year 2024, and net income of 92.04 billion KRW. That is a net profit margin of 26.3% for fiscal year 2024. In Q3 2025 (the quarter ended September 30, 2025) revenue was 135.43 billion KRW, up 51.8% from a year before. South Korea was its largest region in fiscal year 2025, with 61% of revenue. In Q3 2025 it reported net income of 48.97 billion KRW, against net income of 24.72 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 194.76 billion KRW in fiscal year 2022 to 350.12 billion KRW in fiscal year 2024, 34.1% a year on average. PharmaResearch reports about 549 full-time employees.

What stands out

  • Revenue rose 34.1% in fiscal year 2024, from 261.01 billion KRW in fiscal year 2023, after a rise of 34.0% the year before.

Figures from company filings; latest fiscal year ended December 31, 2024.

About PharmaResearch Co., Ltd.

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

Largest shareholders

  • Sang-Soo Jung34.28 %34.28%
  • Polish Co. Ltd.11.32%
  • Seung-Geol Baek0.3369 %0.34%
  • Deka Vermögensmanagement GmbH0.21%
  • Yu-Jin Jung0.0969 %0.10%

Share of the company, as of September 25, 2026

Leadership

  • Sang-Soo Jung — Chief Executive Officer, 67

How much revenue does PharmaResearch make?

PharmaResearch reported 350.12 billion KRW in revenue for fiscal year 2024, up 34.1% from 261.01 billion KRW in fiscal year 2023. In Q3 2025 revenue was 135.43 billion KRW.

Where does PharmaResearch make most of its revenue?

South Korea: 61% of revenue by region in fiscal year 2025, followed by Overseas (39%).

What companies are similar to PharmaResearch?

Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Rokit Healthcare Inc. (376900.KQ), Humedix Co., Ltd. (200670.KQ), Synergy Innovation Co., Ltd. (048870.KQ), Selvas Healthcare, Inc. (208370.KQ).

How has PharmaResearch's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2020, 108.75 billion KRW; FY2021, 154.08 billion KRW; FY2022, 194.76 billion KRW; FY2023, 261.01 billion KRW; FY2024, 350.12 billion KRW.

Company Information

SectorHealthcare
IndustryVarious Healthcare Equipment Manufacturing
Employees549
Founded1993
IPO DateJul 24, 2015
IPO StatusPublic
HeadquartersGangneung-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
77-19, Gwahakdanji-ro, Gangneung-si, 25452
Phone
82 33 645 7640
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “PharmaResearch Co., Ltd. (214450.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/214450.KQ

LinkedInLinkedInXXYouTubeYouTube